Halozyme Therapeutics, Inc.
(NASDAQ : HALO)

( )
HALO PreMarket: $ () as of AM
Volume Open Day's Low Day's High 52 Wk Low 52 Wk High Bid Ask EPS PE Ratio Shares Market Cap Dividend Ex-Div Date Yield
Daily Pre-Market Movers
Receive our daily pre-market mover email, free.
100% secure: your email is never shared, and you may opt out at any time.
...
Health Technology » Biotechnology
symbolcompany%chnglast%shortavg$volume
MRNAModerna, Inc. -0.17%135.570.0%$895.14m
AMGNAmgen, Inc. 0.36%253.951.5%$855.01m
GILDGilead Sciences, Inc. 0.00%64.471.0%$544.83m
VRTXVertex Pharmaceuticals, Inc. 0.32%270.501.9%$489.26m
REGNRegeneron Pharmaceuticals, Inc. 0.05%683.772.6%$434.75m
ILMNIllumina, Inc. 1.76%247.853.3%$318.97m
NVAXNovavax, Inc. -1.08%46.5675.7%$255.64m
BIIBBiogen, Inc. 0.00%204.221.8%$232.70m
BNTXBioNTech SE 0.53%158.990.0%$212.11m
SNSSSunesis Pharmaceuticals, Inc. 0.00%2.100.7%$146.80m
EXASEXACT Sciences Corp. 2.21%50.9617.7%$131.02m
TECHBio-Techne Corp. 0.00%365.324.5%$100.31m
TXG10X Genomics, Inc. 0.00%47.350.0%$95.11m
BMRNBioMarin Pharmaceutical, Inc. 0.00%78.864.2%$94.54m
CRSPCRISPR Therapeutics AG 1.87%56.260.6%$81.90m

Company Profile

Halozyme Therapeutics, Inc. is a biopharmaceutical company, which engages in research, development and commercialization of human enzymes and drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. The firm products include rHuPH20, and HYLENEX recombinant. The company was founded by Gregory Ian Frost on February 26, 1998 and is headquartered in San Diego, CA.